Analyzing...
Loading company...
No significant concerns identified
Nothing flagged for monitoring
“Operates in Pharmaceuticals — Formulations & API.”
₹623 Cr revenue.
COGS 46.7%, employees 18.0%.
“For the INR1,000 crores guideline -- guidance that you have given. So what's the mix? Is it 70-30 or it would be more, say, domestic driven?”
“Our target for INR1,000 crores is still there, and we will achieve it anyhow.”
“On the long-term revenue target, sir, INR1,000 crores, I think earlier, we guided for FY '28. But, yes. So are we still sticking to that year?”
| KPI | Company | Sector Median |
|---|---|---|
| ROE | 12.3%▲ | 10.5% |
| ROCE | 15.7%▲ | 13.8% |
| Net Margin | 12.9%▲ | 8.7% |
| EBITDA Margin | 19.1%▲ | 16.0% |
| Debt To Equity | 0.00x▼ | 0.21x |
| Rev Growth 3yr | 10.2%▲ | 5.8% |
| EPS Growth 3yr | 5.9%▲ | 3.6% |
| (₹ Cr) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2018 |
|---|---|---|---|---|---|---|
| Revenue | ₹652 Cr +4.6% | ₹623 Cr +7.4% | ₹581 Cr +13.8% | ₹510 Cr +8.1% | ₹472 Cr +30.6% | ₹362 Cr |
| Other Income | ₹31 Cr +36.9% | ₹22 Cr -34.7% | ₹34 Cr +53.2% | ₹22 Cr +124.8% | ₹10 Cr +83.3% | ₹5 Cr |
| Total Income | ₹683 Cr +5.7% | ₹646 Cr +5.0% | ₹615 Cr +15.4% | ₹533 Cr +10.5% | ₹482 Cr +31.3% | ₹367 Cr |
| COGS | ₹302 Cr +3.7% | ₹291 Cr +4.7% | ₹278 Cr +15.3% | ₹241 Cr +10.4% | ₹219 Cr +13.5% | ₹193 Cr |
| ₹568 Cr +5.8% | ₹537 Cr +8.9% | ₹493 Cr +14.0% | ₹432 Cr +11.9% | ₹386 Cr +20.4% | ₹321 Cr | |
| Profit Before Tax | ₹115 Cr +5.5% | ₹109 Cr -10.7% | ₹122 Cr +21.7% | ₹100 Cr +4.7% | ₹96 Cr +107.4% | ₹46 Cr |
| ₹27 Cr +1.8% | ₹27 Cr -7.2% | ₹29 Cr +4.9% | ₹28 Cr +3.7% | ₹27 Cr +129.2% | ₹12 Cr | |
| Net Profit | ₹88 Cr +6.7% | ₹82 Cr -11.7% | ₹93 Cr +28.0% | ₹73 Cr +5.1% | ₹69 Cr +100.2% | ₹35 Cr |
| Profit (Owners) | ₹88 Cr +6.7% | ₹82 Cr -11.7% | ₹93 Cr +28.0% | ₹73 Cr +5.1% | ₹69 Cr +100.3% | ₹35 Cr |
| Other Comprehensive Income | ₹0.11 Cr +25.0% | ₹0.09 Cr +50.1% | ₹0.06 Cr ↑ Recovery | (₹0.30 Cr) ↓ Decline | ₹0.13 Cr +31.7% | ₹0.10 Cr |
| EPS | ₹43.86 | ₹41.11 | ₹46.58 | ₹36.40 | ₹34.63 | ₹17.31 |
| Diluted Shares | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr | ₹2 Cr |
No related party data available for this company.
This section will be populated when data becomes available.
Lincoln Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication with respect to Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Y...
Lincoln Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
Lincoln Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Lincoln Pharmaceuticals Limited has informed the Exchange about Transcript of the investor meet held on February 18, 2026.
Lincoln Pharmaceuticals Limited has informed the Exchange about Link of Recording for the Investor call held today.
Lincoln Pharmaceuticals Limited has informed the Exchange about Schedule of Earnings Conference Call to discuss the unaudited financial results of the Company for the Quarter and Nine months ended Dec...
Lincoln Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication
Lincoln Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended December 31, 2025.
Lincoln Pharmaceuticals Limited has informed the Exchange about Credit Rating
The Exchange has sought clarification from Lincoln Pharmaceuticals Limited for the quarter ended 30-Sep-2025 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements)...
Lincoln Pharmaceuticals Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018
Lincoln Pharmaceuticals Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
Lincoln Pharmaceuticals Limited has informed the Exchange about Copy of Newspaper Publication with respect to unaudited financial results of the company for the quarter and half year ended on 30.09.20...
Lincoln Pharmaceuticals Limited has submitted to the Exchange, the financial results for the period ended September 30, 2025.
Lincoln Pharmaceuticals Limited has informed the Exchange regarding Minutes of Annual General Meeting held on September 30, 2025.
Disclaimer · The Stock Filter is an information platform, not a SEBI-registered investment adviser. All data, scores, and narratives are generated from public filings and AI analysis — they do not constitute investment advice, recommendations, or endorsements. Always consult a qualified financial adviser before making investment decisions. Past performance does not guarantee future results.